Protara Therapeutics shareholders elect three directors, ratify auditor, approve say-on-pay at 2022 annual meeting

Protara Therapeutics, Inc.

Elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors to serve until 2025 annual meeting.
Ratified Ernst & Young as independent registered public accounting firm for fiscal year ending Dec 31, 2022 with 8,385,650 votes for.
Advisory vote approved compensation of named executive officers with 6,426,881 votes for, 126,276 against, 54,902 abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.